国产精品av在线观看不_日韩久久美女毛片_黄色网站在线性爱视频_9691精品人妻无码久久久_成年AV免费网址大全超清_亚洲aⅴ天堂无码_曰本裸色私人影院噜噜噜影院_另类视频无码视频国产精品_网红三级在线播放_美腿丝袜在线观看

Entries by

EISAI RECEIVES THE PRESIDENT’S AWARD OF THE JAPAN TECHNO-ECONOMICS SOCIETY AT THE 8TH TECHNOLOGY MANAGEMENT AND INNOVATION AWARDS

FOR ITS CONTRIBUTIONS TOWARDS PATIENTS WITH LIVER DISEASE THROUGH THE EISAI-ORIGINATED ORALLY AVAILABLE KINASE INHIBITOR LENVIMA?

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it received the President’s Award at the 8th Technology Management and Innovation Awards held by the Japan Techno-Economics Society (JATES)*. The award was presented to Eisai for its discovery of the orally available kinase inhibitor LENVIMA?(generic name: lenvatinib mesylate) and its contributions towards patients with liver disease.

2020/2/21 by

LAUNCH OF ANTICANCER AGENT HALAVEN? IN CHINA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has launched the in-house developed anticancer agent Halaven??(product name in China: 海樂衛(wèi)?, generic name: eribulin mesylate) in China.

2020/1/10 by

FYCOMPA? FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED IN CHINA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has launched the in-house discovered and developed antiepileptic drug (AED) Fycompa?, (product name in China: 衛(wèi)克泰?, generic name perampanel) for use in adjunctive treatment of partial onset seizures (with or without secondarily generalized seizures) in epilepsy patients 12 years of age and older.

2020/1/6 by

U.S. FDA APPROVES EISAI’S DAYVIGO? (LEMBOREXANT) FOR TREATMENT OF INSOMNIA IN ADULT PATIENTS

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) today announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for its in-house discovered and developed orexin receptor antagonist DAYVIGOTM(lemborexant). DAYVIGO was approved for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults1. In the United States, DAYVIGO will be commercially available in 5 mg and 10 mg tablets following scheduling by the U.S. Drug Enforcement Administration (DEA), which is expected to occur within 90 days.

2019/12/23 by

Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu; “Sysmex”) and Eisai Co., Ltd. (HQ: Tokyo, Japan; CEO: Haruto Naito; “Eisai”) announced that the most recent data from the project to develop a method of diagnosing Alzheimer’s disease (AD) using blood plasma was presented at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) conference, held virtually from November 4 to 7, 2020.

2019/12/9 by

Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood

Sysmex Corporation (HQ: Kobe, Japan; Chairman and?CEO: Hisashi Ietsugu; “Sysmex”) and Eisai Co., Ltd. (HQ: Tokyo, Japan;?CEO: Haruo Naito; “Eisai”) are pursuing a joint project to develop a method of diagnosing Alzheimer’s disease (AD) using blood, presented two posters showing the most recent data from the project. The presentations took place at the 12th?Clinical Trials on Alzheimer’s Disease (CTAD) conference, from December 4 to 7, 2019, in San Diego, California. At?CTAD,?Sysmex demonstrated on behalf of the two companies the possibility of understanding amyloid pathology in the brain from the brain-derived amyloid beta (Aβ) in plasma measured using its protein measurement platform, the?HISCL? series of fully automated immunoassay analyzers.

2019/12/9 by

EISAI TO PRESENT NEW RESEARCH ON ERIBULIN (HALAVEN?) AT 42ND ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the latest information on its in-house discovered and developed eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN?, “eribulin”) will be presented during the 42nd San Antonio Breast Cancer Symposium (SABCS2019). The symposium will be held from December 10 through 14, 2019, in San Antonio, Texas in the United States.

2019/12/5 by

EISAI TO PRESENT LATEST DATA ON ALZHEIMER’S DISEASE / DEMENTIA PIPELINE AT 12TH CLINICAL TRIALS ON ALZHEIMER’S DISEASE CONFERENCE

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that three oral presentations and eight poster presentations, highlighting the latest data on its Alzheimer’s disease / dementia pipeline including anti-amyloid beta (Aβ) protofibril antibody BAN2401, orexin receptor antagonist lemborexant and a simple blood diagnostic for Alzheimer’s disease (AD), will be given at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) conference taking place in San Diego, California in the United States, from December 4 to 7, 2019. BAN2401 is being jointly developed by Eisai and Biogen Inc.

2019/12/2 by

ADDITIONAL INDICATION FOR LENVIMA? (LENVATINIB) FOR DIFFERENTIATED THYROID CANCER ACCEPTED IN CHINA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced that LENVIMA (generic name: lenvatinib), the orally available kinase inhibitor discovered by Eisai, has been accepted by the National Medical Products Administration of China for an application for the additional indication of differentiated thyroid cancer. This application for additional indication marks the second in China following the indication for hepatocellular carcinoma, which was approved in September 2018.???

2019/12/2 by